New drug approved to treat HIV-1

August 13, 2013

(HealthDay)—Tivicay (dolutegravir) has been approved by the U.S. Food and Drug Administration to treat infection with HIV-1, a strain of the virus that causes AIDS.

The drug, among a class called integrase strand transfer inhibitors, interferes with an enzyme that HIV needs to multiply. It's been approved in combination with other and for people aged 12 and older who weigh at least 40 kilograms (approximately 88 pounds), the FDA said in a news release.

Some 50,000 Americans acquire HIV infection each year, and about 15,500 people died from the disease in 2010, the agency said, citing the U.S. Centers for Disease Control and Prevention.

The drug's safety and effectiveness were evaluated in clinical studies involving more than 2,500 adults and children, the FDA said. The most common side effects included difficulty sleeping, headache and more serious problems including allergic-like reactions and abnormal liver function in people who had hepatitis B or C.

Tivicay is produced by GlaxoSmithKline, based in Research Triangle Park, N.C.

Explore further: FDA approves rapid diagnostic test for HIV antigen, antibodies

More information: The U.S. Department of Health and Human Services's website has more about HIV/AIDS.

Related Stories

New test IDs genotype of hepatitis C

June 20, 2013

(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Vibativ approved for certain bacterial pneumonia

June 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

Researchers use CRISPR to accelerate search for HIV cure

October 25, 2016

Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.

Study unlocks secret of common HIV strain

October 13, 2016

A discovery that the most common variant of the HIV virus is also the "wimpiest" will help doctors better treat millions of individuals around the world suffering from the deadly disease, according to one of the world's leading ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.